Technical feasibility study for an at-home multiplex lateral flow test for monitoring biomarkers in menstrual blood for polycystic ovary syndrome.

用于监测经血中多囊卵巢综合征生物标志物的家庭多重侧向层析测试的技术可行性研究。

• 批准号: 10043120
• 金额: $ 6.37万
• 依托单位: WOOST LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10043120
• 关键词: Technical; feasibility; study; home; multiplex

Woost Ltd is a new fem-tech start-up who are dedicated to the development of novel technologies to significantly improve the awareness and diagnosis of gynaecological health conditions starting with polycystic ovary syndrome (PCOS), an ovarian dysfunction. We are devoted to building a community, in which women's health concerns are effectively targeted and more importantly, being heard.In the current healthcare ecosystem women experiencing any symptoms have to overcome restrictions on availability and accessibility and travel to the doctor's office to receive medical help. After attending their appointments, 4 in 5 women felt they were not properly listened to by healthcare professionals leading to disheartening experiences women have been through from their long journey to diagnosis. PCOS has a direct relation to the emergence of life-threatening diseases (e.g. diabetes) and thus an earlier diagnosis is tremendously important for women's quality of life. And yet, the pandemic further limited the accessibility to healthcare and enhanced concerns around the resulting delayed diagnoses for these women.Woost's mission is to eliminate these restrictions and provide women the support they need to take control of their own health journey. We put women at the centre of their healthcare needs by directly offering them diagnostic tools to understand the basis of their symptoms. Women can join our digital platform and order our at-home test kits to examine menstrual blood for an earlier diagnosis of PCOS. Having access to their results from the comfort of their home eliminates any previously experienced location- and time-specific constraints and facilitates an earlier and more detailed diagnosis of gynaecological conditions. Providing remote triage, we are removing the need for clinicians to perform routine analytical testing and thus we are increasing the time clinicians can now spend on patient engagement and disease treatment. Woost's menstrual blood tests will be easy-to-use, affordable and accessible to be used by any woman anywhere to monitor their gynaecological well-being.

Woost Ltd是一家新的女性科技初创公司，致力于开发新技术，以显着提高对多囊卵巢综合征（PCOS），卵巢功能障碍的妇科健康状况的认识和诊断。我们致力于建立一个社区，在这个社区中，女性的健康问题得到有效关注，更重要的是，被倾听。在当前的医疗保健生态系统中，出现任何症状的女性都必须克服可用性和可及性方面的限制，前往医生办公室接受医疗帮助。在参加预约后，五分之四的女性认为他们没有得到医疗保健专业人员的适当倾听，导致女性在漫长的诊断过程中经历了令人沮丧的经历。PCOS与危及生命的疾病（如糖尿病）的出现有直接关系，因此早期诊断对妇女的生活质量非常重要。然而，疫情进一步限制了这些女性获得医疗保健的机会，并加剧了人们对由此导致的延迟诊断的担忧。Woost的使命是消除这些限制，并为女性提供所需的支持，以控制自己的健康之旅。我们将女性置于其医疗保健需求的中心，直接为她们提供诊断工具，以了解其症状的基础。女性可以加入我们的数字平台，并订购我们的家庭检测试剂盒，以检查经血，从而更早地诊断PCOS。在舒适的家中获得他们的结果消除了任何以前经历的特定地点和时间的限制，并有助于更早和更详细地诊断妇科疾病。通过提供远程分诊，我们消除了临床医生进行常规分析测试的需要，因此我们增加了临床医生现在可以用于患者参与和疾病治疗的时间。Woost的经血测试将易于使用，负担得起，可供任何地方的任何妇女使用，以监测她们的妇科健康。